Epigral Limited

rs,

oor- 25, P J Tower, Dalal Street, Mumbai 400 001 SYMBOL:- EPIGRAL Scrip Code: 543332 Dear Sirs, Sub.: Investors Presentation on Audited Financial Results – Q4 & FY2026 Ref.: Regulation 30 of the

15%

s. Q4 and FY2026 Result update Key Highlights Q4FY26 Key Highlights: o QoQ sales volume grew by 15% and overall plant utilization stood above 80% o Highest ever revenue of ₹ 736 Crore, a 22% growth,

80%

s Q4FY26 Key Highlights: o QoQ sales volume grew by 15% and overall plant utilization stood above 80% o Highest ever revenue of ₹ 736 Crore, a 22% growth, due to volume growth and improved realization

₹ 736 Crore

Q sales volume grew by 15% and overall plant utilization stood above 80% o Highest ever revenue of ₹ 736 Crore, a 22% growth, due to volume growth and improved realization o Revenue contribution from Derivativ

22%

grew by 15% and overall plant utilization stood above 80% o Highest ever revenue of ₹ 736 Crore, a 22% growth, due to volume growth and improved realization o Revenue contribution from Derivatives & Sp

54%

and improved realization o Revenue contribution from Derivatives & Specialty business increased to 54% in Q4FY26 vs 52% in Q3FY26 o Absolute EBITDA grew by 64% to ₹ 169 Crore vs ₹ 103 Crore in Q3FY26.

52%

ization o Revenue contribution from Derivatives & Specialty business increased to 54% in Q4FY26 vs 52% in Q3FY26 o Absolute EBITDA grew by 64% to ₹ 169 Crore vs ₹ 103 Crore in Q3FY26. o EBITDA margin

64%

vatives & Specialty business increased to 54% in Q4FY26 vs 52% in Q3FY26 o Absolute EBITDA grew by 64% to ₹ 169 Crore vs ₹ 103 Crore in Q3FY26. o EBITDA margin stood at 23% vs 17% in Q3FY26, on accoun

₹ 169 Crore

& Specialty business increased to 54% in Q4FY26 vs 52% in Q3FY26 o Absolute EBITDA grew by 64% to ₹ 169 Crore vs ₹ 103 Crore in Q3FY26. o EBITDA margin stood at 23% vs 17% in Q3FY26, on account of improved u

₹ 103 Crore

siness increased to 54% in Q4FY26 vs 52% in Q3FY26 o Absolute EBITDA grew by 64% to ₹ 169 Crore vs ₹ 103 Crore in Q3FY26. o EBITDA margin stood at 23% vs 17% in Q3FY26, on account of improved utilization leve

23%

o Absolute EBITDA grew by 64% to ₹ 169 Crore vs ₹ 103 Crore in Q3FY26. o EBITDA margin stood at 23% vs 17% in Q3FY26, on account of improved utilization level and normalized inventory cost o PAT ro

17%

olute EBITDA grew by 64% to ₹ 169 Crore vs ₹ 103 Crore in Q3FY26. o EBITDA margin stood at 23% vs 17% in Q3FY26, on account of improved utilization level and normalized inventory cost o PAT rose by 1

“EcoVadis Silver Medal 25% 17% 5 Year Revenue CAGR (FY26) 5 Year EBITDA CAGR (FY26) 0.9x 16% Net Debt to EBITDA (FY26) ROCE (FY26) Revenue (₹ Crore) 2,196 1,936 1,555 2,565 2,542”

“Balance Sheet Liabilities (₹ Crore) FY24 FY25 FY26 Assets (₹ Cr) FY24 FY25 FY26 Share Capital 42 43 43 Fixed Assets 2,249 2,302 2,568 Reserves & Surplus 1,213 1,860 2,178 Financial Assets Long-Term Borrowings Redeemable Pref.”

Founded

1

Employees

1

Certified

1

Manufacturing facility

1

Integration

1

New Value Chains

1

Certified

EcoVadis Silver Medal 25% 17% 5 Year Revenue CAGR (FY26) 5 Year EBITDA CAGR (FY26) 0.9x 16% Net Debt to EBITDA (FY26) ROCE (FY26) Revenue (₹ Crore) 2,196 1,936 1,555 2,565 2,542

Manufacturing facility

Fully-integrated & automated complex FY22 FY23 FY24 FY25 FY26 # Chlor-Alkali : Caustic Soda - 400 KTPA and Caustic Potash - 21 KTPA Derivatives : CPVC Resin – 75 KTPA, Epichlorohydrin – 50 KTPA, Chlorotoluenes Value Chain – 15 KTPA, Chloromethanes - 50 KTPA and Hydrogen Peroxide - 60 KTPA Our Journey FY 2007 FY 2010 FY 2015 FY 2017 FY 2020 Epigral Ltd (MFL) incorporated Commissioned 1st Plant • Caustic Soda – 119 KTPA • CPP – 40 MW Increased capacity to • Caustic Soda – 167 KTPA • CPP – 60 MW Commissioned • Caustic Potash – 21 KTPA Commissioned • Chloromethanes – 50 KTPA Converted all Membrane to Zero Gap FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 Commissioned • Hydrogen Peroxide – 60 KTPA Listed as an independent entity on 18th August 2021 Commissioned • Epichlorohydrin – 50 KTPA • CPVC Resin – 30 KTPA Renamed company from Meghmani Finechem to Epigral Increased capacity to • Caustic Soda – 294 KTPA • CPP 96 MW Awarded “Responsible Care” Certificate Increased capacity to Caustic Soda – 40

Integration

o Scale up capacities in existing products o New value added products in existing value chains o Improved market position Opportunities in high growth sectors: o Explore opportunities in various sectors o Increase presence & improve market share o Entering into products which are fully imported

New Value Chains

o Expand chemistry expertise to enter new value chains (specialty chemicals) o Addition of new reaction capabilities Achieving economies of scale: o Optimising existing complex o Achieving efficiency operations to become a low cost producer Historical numbers Financial Performance – P&L Revenue (₹ Crore) EBITDA (₹ Crore and %) PAT (₹ Crore and %) 2,565 2,542 2,196 1,936 1,555 33% 31% 689 509 25% 479 28% 711 22% 567 16% 16% 14% 13% 353 253 10% 196 357 333 FY2022 FY2023 FY2024 FY2025 FY2026 FY2022 FY2023 FY2024 FY2025 FY2026 FY2022 FY2023 FY2024 FY2025 FY2026* Margin -% *As the company shifted to new tax rate of 25.17%, deferred tax liability reduced by Rs. 81 Cr, resulting in PAT of Rs. 333 Cr. If we exclude the reduction of deferred tax liability, PAT would be of Rs. 252 Cr for FY2026. Balance Sheet Ratios ROCE (%)# ROE (%) Net Debt/EBITDA (x) 32% 29% 39% 36% 25% 17% 16% 23% 17% 16% 1.9 2.0 1.3 0.9 0.7 FY2022 FY2023 FY2024 FY2025 FY2026 FY2022 FY2023 FY2024 FY2025 FY2026 FY2022 FY2023